Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus LMB chemotherapy in high-risk pediatric B-cell NHL or B-cell acute leukemia
jRCTs041180089Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in mature B-cell lymphoma and Acute Leukaemia, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Event-free survival. Started Jun 2016; status: completed.
02
Drugs
rituximab
03
Conditions
mature B-cell lymphomaAcute Leukaemia
Beyond the preview
Go deeper on jRCTs041180089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180089.